Compare PAHC & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAHC | ENOV |
|---|---|---|
| Founded | 1946 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2014 | 2008 |
| Metric | PAHC | ENOV |
|---|---|---|
| Price | $40.78 | $27.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $31.25 | ★ $49.14 |
| AVG Volume (30 Days) | 273.3K | ★ 854.1K |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 288.74 | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | $1,399,676,000.00 | ★ $2,233,266,000.00 |
| Revenue This Year | $15.34 | $9.27 |
| Revenue Next Year | $3.28 | $4.56 |
| P/E Ratio | $24.30 | ★ N/A |
| Revenue Growth | ★ 33.72 | 11.57 |
| 52 Week Low | $16.16 | $25.47 |
| 52 Week High | $46.42 | $49.38 |
| Indicator | PAHC | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 43.46 |
| Support Level | $39.39 | $25.52 |
| Resistance Level | $41.62 | $28.02 |
| Average True Range (ATR) | 1.66 | 1.28 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 63.50 | 31.79 |
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.